SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Nov 25, 2011
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: Nov. 25, 2011 · CIK: 0001213037 · Accession: 0001104659-11-066180
AI Filing Summary & Sentiment
Letter
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, NY 10006
November 23, 2011
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549-4720
Re:
TrovaGene, Inc.
Registration Statement on Form 10
Ladies and Gentlemen:
TrovaGene, Inc. (the “Company”) is filing its registration statement on Form 10 via EDGAR concurrently with this transmittal letter. The Company, formerly known as Xenomics, Inc., previously filed periodic reports with the SEC pursuant to Section 15(d) of the Securities Exchange of 1934 since it became subject to such requirements after the effective date of its first registration statement under the Securities Act of 1933 on May 19, 2003. The Company, as a result of financial difficulties and the inaction of prior management, has not filed a periodic report containing financial statements of the Company subsequent to the filing of the Form 10-Q for the quarterly period ended October 31, 2006.
In October 2009, I had a conversation with the Staff on the best approach to bringing the Company’s filing current and the Staff concurred with counsel’s opinion that the Company file a Form 10 registration statement. The Company will be filing an amendment to Form 10 as soon as possible in order to incorporate September 30, 2011 and 2010 interim financial statements prior to effectiveness.
Sincerely,
/s/ Jeffrey J. Fessler
Show Raw Text
CORRESP 1 filename1.htm Sichenzia Ross Friedman Ference LLP 61 Broadway, 32nd Floor New York, NY 10006 November 23, 2011 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Re: TrovaGene, Inc. Registration Statement on Form 10 Ladies and Gentlemen: TrovaGene, Inc. (the “Company”) is filing its registration statement on Form 10 via EDGAR concurrently with this transmittal letter. The Company, formerly known as Xenomics, Inc., previously filed periodic reports with the SEC pursuant to Section 15(d) of the Securities Exchange of 1934 since it became subject to such requirements after the effective date of its first registration statement under the Securities Act of 1933 on May 19, 2003. The Company, as a result of financial difficulties and the inaction of prior management, has not filed a periodic report containing financial statements of the Company subsequent to the filing of the Form 10-Q for the quarterly period ended October 31, 2006. In October 2009, I had a conversation with the Staff on the best approach to bringing the Company’s filing current and the Staff concurred with counsel’s opinion that the Company file a Form 10 registration statement. The Company will be filing an amendment to Form 10 as soon as possible in order to incorporate September 30, 2011 and 2010 interim financial statements prior to effectiveness. Sincerely, /s/ Jeffrey J. Fessler Jeffrey J. Fessler cc: Antonius Schuh